Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures, and markets prescription drugs. It offers products in the therapeutic areas of cardio-cerebral vascular, anti-infective, digestive system, metabolism, respiratory, neurology and other. Sihuan Pharmaceutical offers products under the brand names Tenedid, Tenaxin, Xiangtong, Aogan, Aohuan, Aomeina, Ren'ao, Ashenqnuooqi, Aosaixin, and Huineng among others. The company sells its products through its distribution to network hospitals and medical institutions in Zhejiang, Guangdong, and Henan. Sihuan Pharmaceutical is headquartered in Beijing City, Beijing, China.
Headquarters
China
Address
Floor 22, Building 4, Zhubang 2000, Balizhuang xili, Beijing, 100025
Website
www.sihuanpharm.com
Telephone
86 010 57693700
No of Employees
2,843
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
460 (HKG)
Revenue (2024)
$364.3M
37.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
182.9%
(2024 vs 2023)
Market Cap*
$1.0B
Net Profit Margin (2024)
XYZ
160.2%
(2024 vs 2023)
* As of and is in US$
Sihuan Pharmaceutical Holdings Group Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cardio-Cerebral Vascular | Tenedid |
| Neurology | Tenaxin |
| Digestive System | Xiangtong |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In November, the company announced its plans to spin off the shares of Xuanzhu Biopharm. |
| 2023 | Regulatory Approval | In October, the company and its subsidiaries announced that the investigational new drug application of insulin degludec and liraglutide injection was approved by the National Medical Products Administration of the People’s Republic of China. |
| 2022 | Contracts/Agreements | In May, the company’s subsidiary Xuanzhu Bio and SignalChem cooperate to develop drug XZB-0004, approved for clinical trials of advanced solid tumors and hematological malignancies. |
Competitor Comparison
| Key Parameters | Sihuan Pharmaceutical Holdings Group Ltd | China National Medicines Corporation Ltd | Zhejiang Hisun Pharmaceutical Co Ltd | Tong Ren Tang Technologies Co Ltd | Luye Pharma Group Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | Hong Kong |
| City | Beijing | Beijing | Taizhou | Beijing | Hong Kong City |
| State/Province | Beijing | Beijing | Zhejiang | Beijing | - |
| No. of Employees | 2,843 | 3,024 | 8,751 | 3,951 | 5,221 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Che Fengsheng | Chairman | Executive Board | 2006 | 63 |
| Guo Weicheng | Chief Executive Officer; Deputy Chairman | Executive Board | 2006 | 61 |
| Miao Guili | Deputy Chief Executive Officer; Chief Financial Officer; Director | Executive Board | 2022 | 51 |
| Zhang Jionglong | Director | Executive Board | 2018 | 63 |
| Chen Yanling | Director; Secretary | Executive Board | 2018 | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer